PHOENIX and VANCOUVER, B.C., Jan. 18, 2017 -- Eternity Healthcare Inc. (OTC:ETAH), announces first regulatory approval of its Loader for the Lenis® Needle-Free Injection system.
“CE Certification opens the door for regulatory approval in the EU as well as other countries that follow the EU. With the most difficult components already certified, we remain confident the final two certifications should come later this year, along with final approval, setting us up for the start of Marketing our device,” Said Dr. Salari, President & CEO
The Loader unit of the Lenis® injection system that is used to load the injector to be ready for injection concluded rigorous testing with major ISO auditing company and passed all requirements for approval.
The Lenis® Needle-Free Injection system is comprised of four major components. With the second component receiving CE Certification, we are looking forward to approval of the remaining two units.
“We believe Lenis® will revolutionize medical injections, removing patient fear of needles along with substantial reduction in cost per injection. The injection systems market was estimated at $9.8 Billion for 2016 and is expected to grow at 15.5% until reaching $20.17 Billion in size by 2021. Unlike our competition, our design allows for delivery of higher doses, meaning Lenis® could be used with traditional needles and syringes used worldwide. We’re confident we have a superior technology,” said Dr. Salari.
Needle-Free Injection System Applications
The Needle-Free Injection system can be used for a vast variety of injectable medications, and supplements. These include injection of Insulin for diabetes, injection of vaccines such as flu vaccine and many others, injection of steroids, vitamins, human growth hormones, infertility medications and a vast number of cancer drugs. Further applications such as injection of epinephrine might replace Auto-Injectors such as Mylan’s Epipen®.
Benefits of Needle-Free Injection System
The Needle-Free injection system has many advantages over the existing needle injection. These include being environmentally friendly and reducing the risk of accidental poking and cross contamination. Further, the Needle-Free Injection device is good for children and people with needle phobia. It is easy to discard the used syringes as well as to recycle them.
About Eternity Healthcare
Eternity Healthcare or the “Company” (OTC:ETAH) is a healthcare company with technologies in medical devices. Our most advanced product is a Needle-Free Injection system known as Lenis®. Our products are targeted for use by the healthcare professionals, physicians and consumers directly. More information on Eternity Healthcare, visit the Company’s website; www.eternityhealthcare.com
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Company Contact: Dr. Salari President & CEO (604) 324 -1113 [email protected] [email protected]


FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 



